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Background: The HMGA2 protein has experimentally been linked to EMT and cancer stemness. Recent studies imply that
tumour–stroma interactions regulate these features and thereby contribute to tumour aggressiveness.
Methods: We analysed 253 cases of pancreatic ductal adenocarcinoma (PDAC) and 155 cases of ampullary adenocarcinoma
(AAC) for HMGA2 expression by IHC. The data were correlated with stroma abundance and supplemented by experimental
studies.
Results: HMGA2 acts as an independent prognostic marker associated with a significantly shorter overall survival in both tumour
types. Overall, HMGA2-positivity was more frequent in patients with PDAC than with AAC. The HMGA2 status in tumour cells
significantly correlated with the abundance of PDGFRb-defined stroma cells. In vivo co-injection of Panc-1 cancer cells with
pancreatic stellate cells increased tumour growth in a manner associated with increased HMGA2 expression. Furthermore, in vitro
treatment of Panc-1 with conditioned media from PDGF-BB-activated stellate cells increased their ability to form tumour spheroids.
Conclusions: This study identifies HMGA2 expression in tumour cells as an independent prognostic marker in PDAC and AAC.
Correlative data analysis gives novel tissue-based evidence for a heterotypic cross-talk with stroma cells as a possible mechanism
for HMGA2 induction, which is further supported by experimental models.
The most frequent forms of cancer in the pancreatic region are the
pancreatic ductal adenocarcinoma (PDAC; 70%) followed by the
ampullary adenocarcinoma (AAC; 12%). PDAC is the fourth most
common cause of cancer death in Europe (Ferlay et al, 2010;
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Rostain et al, 2014; Ryan et al, 2014; Malvezzi et al, 2016; Siegel
et al, 2016).
PDAC and AAC are very aggressive diseases with high
metastatic potential and almost complete resistance to chemother-
apy. Only 7% of all PDAC patients survive longer than 5 years
(Lepage et al, 2015). The absence of symptoms in the early stages
leads to late clinical presentation, and most patients have locally
advanced or metastatic disease at time of diagnosis. As a
consequence only 15–20% of PDAC patients receive curative
surgery and even among those the 5-year survival rate is less than
20% (Li et al, 2004; Wagner et al, 2004). In contrast, the AAC
usually causes earlier symptoms and more patients are diagnosed
at earlier stages and can receive curative surgery (Howe et al, 1998).
Therefore the prognosis for AAC is more favourable withB41% of
the patients surviving 5 years after curative resection (Rostain et al,
2014).
Only few reliable prognostic or predictive biomarkers have been
established for cancers in the pancreatic region, as, for example,
DPC4/SMAD4 expression (Tascilar et al, 2001; Biankin et al, 2002;
Iacobuzio-Donahue et al, 2009).
The high-motility group A 2 (HMGA2) protein belongs to the
family of non-histone chromosomal high-mobility group proteins
(reviewed in Bustin and Reeves, 1996; Bustin, 1999; Cleynen and
Van de Ven, 2008; Reeves, 2015), which function as architectural
factors that alter DNA structure and thereby regulate DNA-
dependent activities, like transcription, replication and repair
(Cleynen and Van de Ven, 2008). HMGA2 contains a structural
DNA-binding motif, the AT hook, which enables binding to the
minor groove of AT-rich DNA regions (Reeves, 2001). It
furthermore promotes the recruitment of additional transcriptional
regulators and interacts in multiple protein complexes on
promoter/enhancer sites, forming the so-called enhancosome
(Reeves, 2001; Watanabe et al, 2009). HMGA2 is highly expressed
in the embryo, but is hardly detectable or absent in adult human
tissue, suggesting a role in regulation of cell proliferation and
differentiation (Abe et al, 2003; Cleynen and Van de Ven, 2008).
HMGA2 expression is often re-induced in neoplastic cells and was
shown to be involved in the regulation of epithelial–mesenchymal
transition (EMT) and cancer stem cell properties (Thuault et al,
2006; Watanabe et al, 2009; Madison et al, 2015).
Over-expression of HMGA2 has been described to be associated
with metastasis and poor prognosis, for example, in triple negative
breast cancer (Wend et al, 2013), ovarian cancer (Califano et al,
2014), gastric cancer (Motoyama et al, 2008; Lee et al, 2015),
colorectal cancer (Rizzi et al, 2013) and non-small cell lung cancer
(Sarhadi et al, 2006). In PDAC, HMGA2 expression was found to
be associated with lymph node metastases and high tumour grade
(Hristov et al, 2009; Piscuoglio et al, 2012) and with loss of tumoral
E-Cadherin expression (Watanabe et al, 2009). One study,
restricted to 91 cases of PDAC, also detected an association with
poor prognosis in evaluations limited to univariate analysis
(Haselmann et al, 2014).
A massive desmoplastic reaction and stroma formation are
characteristics for PDAC and AAC (Lunardi et al, 2014; Rucki and
Zheng, 2014; Pan et al, 2015) and can also act as a physical barrier
preventing proper delivery of chemotherapeutic agents (Wang
et al, 2016). One major component of the reactive tumour stroma
are cancer-associated fibroblasts (CAFs) and in vitro and in vivo
studies have shown that CAFs have tumour-promoting functions,
including support of growth and metastasis as well as suppression
of immunosurveillance (Ostman and Augsten, 2009; Strell et al,
2012; Weiland et al, 2012; Lunardi et al, 2014; Pan et al, 2015). In
PDAC, SDF-1a (Li et al, 2012) and Nodal/Activin (Lonardo et al,
2011) have been identified as CAF-derived factors that affect EMT
and stem cell properties in cancer cells. More specifically,
pancreatic tumour cells carrying oncogenic KRASG12D were
identified to establish a reciprocal signalling loop with stromal
cells, which regulates tumour cell proliferation and apoptosis (Tape
et al, 2016). Furthermore, fibroblast activation protein-positive
CAFs have been linked to tumour immune evasion (Kraman et al,
2010; Feig et al, 2013) and were found to be associated with a bad
prognosis in PDAC (Kawase et al, 2015). However, two recent
studies also suggested tumour-restraining functions of CAFs in
pancreatic cancer. One study showed that depletion of proliferating
a-smooth muscle actin (ASMA) -positive fibroblasts reduced
fibrosis, but induced immunosuppression and thereby accelerated
an undifferentiated tumour growth, in a mouse model of PDAC
(O¨zdemir et al, 2014). Accordingly, a low stromal ASMA score was
associated with shorter overall survival (O¨zdemir et al, 2014). In
another study, targeted deletion of sonic hedgehog (Shh) or
inhibition of canonical hedgehog signalling, an important regulator
of fibroblasts, resulted in a reduced stroma cell accumulation, but
faster tumour growth and a more undifferentiated phenotype
(Rhim et al, 2014). Together these studies suggest that CAFs can
exhibit different subset-specific tumour regulatory functions.
In the present study, we have characterised HMGA2 expression
in a large collection of PDACs and AACs and related the
expression to clinicopathological features and survival. In both
tumour types, HMGA2-positivity was associated with a signifi-
cantly shorter overall survival. Furthermore, we found that the
HMGA2 status in tumour cells significantly correlated with the
abundance of PDGFRb-defined stroma cells. These findings thus
present novel tissue-based evidence suggesting heterotypic stroma-
epithelial cell cross-talk as a possible mechanism for HMGA2
induction. These findings are supported by experimental studies,
which demonstrate fibroblast-induced regulation of HMGA2
expression, cancer stem cell properties and tumour growth
in vivo and in vitro.
MATERIALS AND METHODS
Patients. Four hundred forty-five patients who underwent
pancreatic resection at Herlev Hospital, University of Copenhagen,
Denmark between 1976 and 2008 (n¼ 277) and at Rigshospitalet,
University of Copenhagen, Denmark between 2004 and 2012
(n¼ 168) were included. Thirty-seven patients were excluded from
the analyses because of an unclear cause of death. Of the included
patients, 253 had PDAC and 155 had AAC. Distinction between
PDAC and AAC was determined by a combination of gross
pathology and microscopy. All tumours were classified and graded
according to the WHO Classification of Tumours. The study was
approved by the local Ethical Committee (H-KA-20060181 and
VEK ref. KA-20060113) and the Danish Data Protection Agency
(j.nr. 2006-41-6848).
Immunohistochemistry (IHC). 4mm whole sections of formalin-
fixed and paraffin-embedded (FFPE) tissue samples were prepared.
IHC was performed on a Ventana autostainer (Ventana Bench-
mark Discovery, NexES V10.6; Tuscon, AZ, USA) using the rabbit
monoclonal anti-HMGA2 antibody (clone D1A7, #8179 Cell
Signaling, Danvers, MA, USA; 1 : 400 dilution) or the rabbit
monoclonal anti-PDGFRb antibody (clone 28E1, #3169 Cell
Signaling; 1 : 100 dilution) diluted in Antibody Diluent Buffer
(Antibody diluent, Ventana). The staining protocol included an
extended antigen retrieval step with CC1/pH9 buffer (Discovery
CC1, Ventana) for HMGA2, or with pH10 Tris buffer (Sigma-
Aldrich and Merck Kgaa, Darmstadt, Germany) for PDGFRb
staining, incubation with the primary antibody for 1 h at room
temperature (RT) and incubation with the secondary antibody
(OmniMab anti-Rb-HRP, Ventana) for 32min at RT.
For each sample the HMGA2 staining was scored as negative or
positive. Samples were defined as positive using a cutoff of X1
positive cell in 10 vision fields of 0.79mm2. The HMGA2 scoring
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approach was discussed with an experienced pathologist for
diseases of the pancreas, ampulla and common bile duct. The
PDGFRb staining was scored as the positive stroma fraction
(negative, low, moderate or high) as previously described (Paulsson
et al, 2009). IHC stainings were scored independently by two
individuals blinded to survival data.
Double IHC staining was performed manually. The slides were
rehydrated and antigen retrieval was performed by heating the
slides in pH10 Tris buffer (Sigma Aldrich) for 5min at 110 1C in a
pressure cooker (HistoLab, Goteborg, Sweden). The slides were
incubated for 30min with serum-free protein blocking reagent
(Dako, Copenhagen, Denmark) at RT. PDGFRb antibody was
diluted 1 : 100 in DAKO REAL antibody diluent (Dako) and
incubated overnight at 4 1C. As a secondary antibody, the
ImmPRESS-AP anti-rabbit IgG (Vector laboratories, Burlingame,
CA, US) was used for 30min at RT. Detection was performed
using the Vector Blue alkaline phosphatase substrate kit (Vector
laboratories) according to the manufacturer’s instructions. In order
to denature primary and secondary antibodies before the second
staining, a further antigen retrieval step was performed for 5min at
95 1C with pH9 retrieval buffer (Dako). Blocking, primary and
secondary antibody incubation were repeated as before but with
the HMGA2 antibody at 1 : 400 dilution. Detection was performed
using the Vector Red alkaline phosphatase substrate kit (Vector
laboratories) according to the manufacturer’s instructions. Hema-
toxylin (Histolab) was shortly applied for 10 s to obtain a weak
counterstain.
For IHC analysis of the Panc-1 xenograft tumours, collected
tumours were inverted in cold isopentane (Sigma-Aldrich) and
embedded in TissueTek (Sakura Finetek USA Inc, Torrance, CA,
USA). Cryosections (4mm) were cut and fixed with acetone
(Sigma-Aldrich) for 15min prior to staining for HMGA2 or
PDGFRb following the same protocol as for FFPE sections. The
digital image analysis for HMGA2-positive areas was performed on
sections before hematoxylin counterstaining. Stained sections of
xenograft tumours were digitalised with the NanoZoomer digital
slide scanner (Hamamatsu City, Japan) and then analysed with the
ImageJ software (Karperien, A., FracLac for ImageJ. http://
rsb.info.nih.gov/ij/plugins/fraclac/FLHelp/Introduction.htm.
1999–2013.) to quantify the brown-stained areas. The data was
normalised to the mean value of the control group for
representation.
KPC mouse model. The mouse line used was KrasLSLG12D/þ ;
Trp53LSLR172H;þ ;Pdx-Cre (KPC) mice (Hingorani et al, 2005).
The mice were maintained at a 12-h-day, 12-h-night cycle on
normal chow ad libidum in line with the local ethical committee
directives (Stockholm so¨dra djurfo¨rso¨ksetiska na¨mnd). Mice were
killed and pancreata were collected at different time points. Tissues
were fixed in 4% para-formaldehyde at RT for 24 h and then
transferred in 70% ethanol for at least another 24 h at 4 1C before
further dehydration and embedding in paraffin.
Cell culture. The Panc-1 PDAC cell line was obtained from
European Selection of Cell Cultures (acacc, # 87092802) and
maintained in Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 10% fetal bovine serum (FBS), 100
units per ml penicillin and streptomycin (P/S) and 2mM
glutamine (all from Hyclone, GE Healthcare, South Logan, UT,
USA). Panc1-H2B-mCherry cells were a kind gift from Dr Maarten
Bijlsma at the Academic Medical Center, Amsterdam, The
Netherlands. The immortalised pancreatic fibroblasts (PSCs)
derived from a patient with chronic pancreatitis as described in
(Jesnowski et al, 2005) were cultured in Dulbecco’s Modified Eagle
Medium: Nutrient Mixture F-12 (DMEM:F12) supplemented with
10% FBS and 100 units per ml P/S.
Limited dilution assay (LDA). Panc-1 cells were detached with
trypsin/EDTA (0.25% trypsin and 0.2 g l 1 EDTA, Hyclone, GE
Healthcare), centrifuged and incubated in dispase (Stem Cell
Technologies, Grenoble, France) for 10min at RT to generate a
single-cell suspension. The dispase treatment was stopped by
addition of two volumes of human NeuroCult NS-A proliferation
media (#05751, Stem Cell Technologies). The cells were further
filtered through a 40-mm cell strainer, counted and seeded in a
descending cell number/well (16, 8, 4, 2, 1) in ultra-low attachment
96-well plates (Corning, Oneonta, New York, NY, USA) in 75 ml of
fibroblast-conditioned or control medium.
Fibroblast-conditioned medium was generated by incubation of
the cells at 75% confluence for 16 h with NeuroCult media without
growth factors. Medium was collected, centrifuged at 4000 r.p.m.
for 10min at 4 1C to remove any cell debris and diluted 1 : 2 with
complete NeuroCult media including 20 ngml 1 EGF and
10 ngml 1 bFGF (both Life Technologies, Carlsbad, CA, USA)
as well as 4 mgml 1 heparin (Stem Cell Technologies). Control
medium was prepared accordingly. Activation of fibroblasts with
50 ngml 1 PDGF-BB (RnD Systems, Minneapolis, MN, USA) was
performed for 6 h and washed away before the collection of
conditioned media.
Fresh conditioned/control medium was added every fifth day.
After 2 weeks, sphere-containing wells were counted and collected
for subsequent RNA isolation.
The data obtained by LDA were analysed with extreme limiting
dilution analysis software (ELDA) (Hu and Smyth, 2009) to
estimate the frequency of sphere forming cells. The data is
presented as the estimated frequency of sphere forming cells±up-
per/lower confidence interval.
Direct co-culture spheroid assay. Panc1-H2B-mCherry cells were
seeded alone or in co-culture with PSCs (1 : 1), at a total
concentration of 2500 cells/well. Non-cell culture treated round
bottom 96-well plates (Falcon, BD NJ, USA) were used, and cells
were seeded in culture media with a final concentration of 0.24%
methylcellulose, as previously described (Longati et al, 2013). After
5 days, the formed spheroids were collected. For dissociation
spheroids were treated twice as follows, 5min incubation in
trypsin/EDTA at 37 1C followed by trituration. The trypsin was
inactivated by the addition of culture media containing 10% FBS.
The cells were collected by centrifugation, washed once with cold
PBS and then re-suspended in cold sorting buffer containing
25mM HEPES, 2mM EDTA and 10 units per ml DNAse II (Sigma
Aldrich) in PBS. Cells were filtered through 50 mm cell strainers
and kept on ice until sorting for mCherry-positive Panc1 cells by
fluorescence activated cell sorting (FACSAria, BD Biosciences,
Franklin Lakes, NJ, USA). Cells from mono-spheroids were also
sorted with the same gating. Sorted cells were collected by
centrifugation for subsequent RNA isolation.
RNA isolation and quantitative reverse transcriptase PCR. RNA
was isolated with GenElute Mammalian Total RNA Miniprep Kit
(Sigma-Aldrich) according to manufacturer’s instructions, includ-
ing DNaseI treatment. RNA concentration was measured with a
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific,
Wilmington, USA). CDNA synthesis from 500 ng RNA was
performed with the SuperScript III Reverse Transcriptase (Life-
Technologies) kit using random hexamer primer according to
manufacturer’s instructions.
For RNA isolation from frozen tumour tissue, B20mg of
tumour tissue was collected from frozen xenograft tumours and
homogenised using a T18 basic Ultra Turrax (IKA, Stauffen,
Germany). Total RNA was isolated using the SV Total RNA
Isolation System (Promega, Madison, WI, USA).
Quantitative real-time PCR was performed using the 2 Power
SYBR Green PCR Master Mix (LifeTechnologies), 200 nM as final
primer concentration and 10 ng of cDNA per 10 ml reaction. The
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real-time PCR primers for human HMGA2, PDGFRb, CK18,
CK19, RPL13a and RPS18 were purchased from Sigma-Aldrich,
the RPL13a primers from Life Technologies and the GAPDH
Quantitec primer from Qiagen (Hilden, Germany). The expression
values were calculated by the comparative DDCT-method for the
gene-of- interest relative to the expression level of the house-
keeping gene. For the HMGA2 determination in xenograft
tumours, results were also corrected for differences in epithelial
fraction by dividing the HMGA2 expression with the expression
average of Cytokeratin (CK)18 and CK19 of the corresponding
samples. Thereafter, the expression-values were normalised to the
mean value of the control group for representation.
Primer Sequences: HMGA2 Fwd 50-CGGCCAAGAGGCA-
GACCTAGG-30 and Rev 50-GTTGGCGCCCCCTAGTCCTCT-30;
PDGFRb Fwd 50-AGGCAAGCTGGTCAAGATCT-30 and Rev
50-GCTGTTGAAGATGCTCTCCG-30; CK18 Fwd 50-TCAGCA
GATTGAGGAGAGCAC-30 and Rev 50-CGTCTCAGCTCTGT
GAGCGTCG-30; CK19 Fwd 50-CATCCAGGACCTGCGGGA
CA-30 and Rev 50-GCGCAGAGCCTGTTCCGTCTC-30; RPS18
Fwd 50-TGAGGTGGAACGTGTGATCA-30 and Rev 50-CCTC
TATGGGCCCGAATCTT-30; RPL13a Fwd 50 AGATGGCG
GAGGTGCAG-30 and Rev 50-GGCCCAGCAGTACCTGTTTA-30.
Xenograft model. Six- to seven-week-old male CB17 SCID mice
(Janvier Labs, Le Genest-Saint-Isle, France) were injected sub-
cutaneously with either 4 106 Panc-1 cells alone or Panc-1
together with PSCs at a 1 : 1 ratio. Each group consisted of five
mice. Tumour growth was monitored two times per week. Tumour
volumes (V) were calculated from the formula (V¼ length
heightwidth/2). The mice were killed under anaesthesia when V
gained approximately 500mm3. Tumours were collected and
immediately snap frozen in liquid nitrogen. The xenograft
experiments were performed in agreement with the local ethical
committee (Utrecht University animal ethical board; ethical permit
number is 2014.III.02.022).
Statistical analysis. Associations between HMGA2 expression and
clinicopathological parameters and PDGFRb expression were
analysed with contingency tables and Fishers’ exact test, two-
sided. The Kaplan–Meier and log rank test were used to compare
cancer-specific survival. A Cox proportional hazards model was
used for estimation of hazard ratios (HR) in both uni- and
multivariate analyses including relevant risk factors as age, sex,
tumour localisation, treatment, stage group and grade of
differentiation in the model. The P-value for cox regression is
based on Wald test. Calculations were performed with the
statistical package IBM SPSS Statistics Version 22 (SPSS Inc.,
Chicago, IL, USA).
The TCGA data on PDAC were used for Kaplan–Meier analysis
and multivariate analysis of overall survival. Cases with histological
subtype other than PDAC were excluded (43 cases excluded out of
197 cases total). Dichotomisation of this data set was performed by
splitting the gene-expression data at the median. The results shown
in Figure 2B are in whole based upon data generated by the TCGA
Research Network: http://cancergenome.nih.gov/.
The GSE21501 data set was only used for Kaplan–Meier analysis
of overall survival. Hundred and two PDAC patients for which
clinical follow-up was available were included. Since only T and
N-stage as additional clinical data was provided no further
multivariate analysis was performed. Dichotomisation of this data
set was performed by splitting the gene-expression data at the
median.
The results from the experimental studies were evaluated by
group comparison using Student’s t-test, two-sided, unpaired.
Two-way ANOVA with Bonferroni post hoc test for comparison
of means was used to evaluate differences in the tumour growth
curves between the two groups of the xenograft model.
Differences with P-valueso0.05 were considered as significant.
RESULTS
HMGA2 expression in cancers of the pancreas and ampulla.
The expression pattern of HMGA2 was analysed by IHC on
tumour sections from 408 patients diagnosed with pancreatic
adenocarcinoma (PDAC; n¼ 253) or AAC (n¼ 155). For each
sample, the staining was scored as negative or positive using a
cutoff of X1 positive cell in 10 vision fields (see Material and
Methods for details).
HMGA2 expression was found in tumour cells, in nuclear
localisation, while it was absent in stroma cells, including
fibroblasts, immune cells and vascular cells. However, the amount
of HMGA2-positive tumour cells varied between cases, and
positive and negative tumours were found both in the PDAC
and AAC group (Figure 1).
Together, these initial analyses thus confirm earlier findings of
variable HMGA2 expression by malignant cells in PDAC (Hristov
et al, 2009; Piscuoglio et al, 2012; Haselmann et al, 2014), and
extend these studies by including AAC in the investigations.
Correlations between HMGA2 expression and clinicopathologi-
cal parameters. A set of analyses was performed to investigate
potential associations between HMGA2 expression and clinico-
pathological features.
A significant association was observed between HMGA2-
positivity and tumour localisation (Table 1). While 56.6% of the
PDAC tumours were positive for HMGA2, only 32.7% of the
AACs were positive (Po0.001; Fishers Exact, two-sided). In
addition, we found overall significant correlations between
HMGA2-positivity and lower tumour differentiation as well as
higher stage group (Po0.001 for differentiation; Po0.028 for stage
group).
The correlation between differentiation and HMGA2-positivity
remained strongly significant only in the group of patients with
PDAC (Po0.001). In the smaller AAC patient group, HMGA2-
positivity was correlated only with older age (Po0.020) (Table 1).
The finding that HMGA2-positivity correlated with lower
tumour cell differentiation prompted analyses on potential
associations between HMGA2 and EMT markers. IHC analyses
combining HMGA2 and cytokeratin antibodies indicated that
HMGA2 expression was not restricted to cells with low cytokeratin
expression (Supplementary Figure 2A). Furthermore, HMGA2
expression was not strongly linked to EMT-associated miRNAs in
the present cohort (Supplementary Figure 2B). Finally, analyses of
the TCGA data set did not detect strong associations between
HMGA2 and selected EMT-related genes (data not shown) or an
established EMT core signature (Taube et al, 2010; Supplementary
Figure 2C).
Together, these analyses demonstrate a relation between
HMGA2 expression and clinicopathological parameters known to
be associated with worse prognosis, such as poor tumour
differentiation and advanced stage group.
HMGA2 expression and overall survival. We used the HMGA2
IHC data together with clinical data on overall survival (OS) with
the aim to investigate a possible prognostic significance of HMGA2
expression in PDAC and AAC.
The presence of HMGA2-positive cells was associated with a
significantly shorter OS in the whole cohort (log Rank Po0.001),
as well as in the patient groups with PDAC (log Rank Po0.001) or
AAC (log Rank Po0.001) (Figure 2A;) separately. In a Cox
Proportional Hazards model, HMGA2-positivity increased
the hazard ratio (HR) for death in the whole cohort (HR 2.29
(1.83–2.86 95% confidence interval); Po0.001). This association
was also detected in separate analysis of patients with PDAC (HR
1.74 (1.33–2.29 95% confidence interval); Po0.001) and AAC (HR
3.12 (2.07–4.70 95% confidence interval); Po0.001) (Figure 2A).
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The associations between poor prognosis and HMGA2-
positivity within the whole cohort remained highly significant in
multivariate analysis, including age, sex, gemcitabine treatment,
grade of differentiation and clinical stage (Po0.001) (Table 2).
Similar results were obtained in analyses in which PDAC and AAC
were evaluated separately (Po0.001 for both PDAC and AAC)
(Table 2).
To obtain independent support of the findings from the IHC
analysis, we used the TCGA PDAC gene-expression data set with
corresponding OS information. Patients with high HMGA2 gene-
expression were found to have a significant shorter OS (log Rank
Po0.009). Also in this cohort, the Cox Proportional Hazards model
showed a significant increased hazard ratio (HR 1.78 (1.15–2.76 95%
confidence interval); Po0.010) in patients with high HMGA2 gene-
expression (Figure 2B), which remained significant in multivariate
analysis (Po0.010) (Supplementary Table 1).
Furthermore, in the GSE21501 cohort, including 102 PDAC
patients, we observed a strong trend towards shorter OS (log Rank
Po0.094) for HMGA2-high patients, which remained in the Cox
Proportional Hazards model (HR 1.50 (0.92–2.45 95% confidence
interval); Po0.103) (Figure 2B).
The analyses thus identify HMGA2-positivity as an independent
prognostic marker for patients with PDAC or AAC.
HMGA2 expression is induced at early stages of tumour
development in a genetic mouse model for PDAC. To the
best of our knowledge, there is no report in the literature at















Figure 1. HMGA2 expression in PDAC and AAC. IHC staining of HMGA2. Positive nuclear staining is detected only in tumour cells. Examples of
negative (left) and positive (right) samples from patients with PDAC (upper rows) and AAC (lower rows) at different magnification. Scale bar,
100mm.
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induced. A set of studies, using both the clinical cohort and the
KPC-model of PDAC, was therefore performed to address this
issue.
The human samples contained predominantly carcinoma and
only small amount of surrounding tissue, limiting the ability to
identify PanIN lesions. However, the detected PanIN-1 and PanIN-
2 lesions were all negative for HMGA2 (n¼ 18; data not shown),
while no PanIN-3 lesions were identified.
In the KPC-model we detected very weak positive staining for
Hmga2-positive tumour cells already in pancreatic intraepithelial
neoplasia (PanIN)-1 lesions (Figure 3), with an increasing
frequency and intensity in PanIN-2 and PanIN-3 lesions. In the
carcinomas we observed heterogeneous staining, with positivity
predominantly in the more poorly differentiated parts (Figure 3).
Therefore, HMGA2 seems to be differentially expressed within
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HR (95%CI) 2.29 (1.83 to 2.86)
Log rank P<0.001
P<0.001
HR (95%CI) 1.74 (1.33 to 2.29)
Log rank P<0.001
P<0.001
HR (95%CI) 3.12 (2.07 to 4.70)
Log rank P<0.094
P<0.103
HR (95%CI) 1.50 (0.92 to 2.45)
Log rank P<0.009
P<0.010
HR (95%CI) 1.78 (1.15 to 2.76)
HMGA2 negative (low)
HMGA2 positive (high)
Figure 2. HMGA2 expression in PDAC and AAC is associated with a shorter cancer-specific survival. (A) Kaplan–Meier graphs of the cancer-
specific survival in HMGA2-negative (black line) and -positive (red line) patients. HMGA2 expression was defined by IHC staining. Survival analyses
were performed on the entire cancer cohort (upper panel) or restricted to the subsets of patients with PDAC (middle panel) and AAC (lower panel).
(B) Kaplan–Meier analyses of overall survival of PDAC patients of the TCGA and GSE21501 cohorts. HMGA2 status is defined as low (black line) or
high (red line) based on gene expression level (see Materials and Methods for cutoff definition). The P values from log-rank tests comparing the
two Kaplan–Meier curves are indicated. The hazard ratio (HR) was calculated with a Cox Proportional Hazards model and the corresponding
P-value is based on Wald test statistic.
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HMGA2-positive cells are located in close proximity to cancer-
associated fibroblasts. PDGFRb is an important regulator of
mesenchymal cells, and is highly expressed on tumour stroma cells
such as cancer-associated fibroblasts (CAFs) and pericytes (Pietras
et al, 2002; Paulsson et al, 2009).
In a case-based analysis, we found a positive association between
the expression of HMGA2 and the abundance of PDGFRb-defined
fibroblasts (Po0.008, Fishers exact test) (Figure 4A).
To investigate the spatial localisation of the two cell types
in more detail, we performed double IHC staining on four different
specimens and found that HMGA2 positive tumour cells appeared
in higher numbers in tumour areas with a strong abundance of
PDGFRb-positive fibroblasts in human PDAC (Figure 4B). How-
ever, one could also detect PDGFRb-positive stromal areas which
were not linked to high expression in the epithelium and vice versa
but these were less frequent (Supplementary Figure 3A).
These observations suggest a role of fibroblasts in the induction
of HMGA2 in tumour cells.
Pancreatic stellate cells support HMGA2 expression and
tumorigenic properties in pancreatic cancer cells. With the aim
to test whether HMGA2 expression and tumourigenic properties of
pancreatic cancer cells are regulated by paracrine interaction, we
performed ‘subcutaneous’ injections of Panc-1 cells either alone or
together with pancreatic stellate cells (PSCs) in SCID mice. Notably,
tumours formed following co-injection grew faster than tumours
derived from Panc-1 mono-injections (310mm3 vs 159mm3 at
collection on day 16 after injection; Po0.05 two-way ANOVA with
Bonferroni post hoc test) (Figure 5A).
Gene expression and protein analysis confirmed a higher
abundance of PDGFRb-positive stroma cells in tumours derived
from co-injection (mRNA level: 4.12-fold increase, Po0.004;
protein based on IHC: 2.1-fold increase, Po0.003; P-values
calculated with Students’ t-Test). Furthermore, the co-injection-
derived tumours showed an increased HMGA2 expression on gene
as well as on protein level (mRNA level: 2.6-fold increase after
correction for epithelial fraction, Po0.012; protein based on IHC:
1.4-fold increase, Po0.019; P-values calculated with Student’s
t-Test) as compared to tumours derived from mono-injection
(Figure 5B and C).
To further analyse a potential impact of PSCs on HMGA2
expression in vitro, we seeded Panc-1 cells under anchorage-
independent conditions in control medium, conditioned medium
from PSCs or conditioned medium from PDGF-BB pre-stimulated
fibroblasts. Panc-1 cells seeded in PSC-conditioned media
displayed an increased ability to form tumour cell spheroids under
anchorage-independent conditions (1/13 cells (11.4–15.7) 95% CI;
Po0.003) than control Panc-1 cells (1/19 cells (16.0–23.0) 95%
CI). This effect was further enhanced with conditioned medium
derived from PSCs pre-stimulated with PDGF-BB (1/10 cells (8.8–
11.8) 95% CI; Po0.001 vs control and Po0.014 vs PSCs)
(Figure 5D). The spheroids grown in conditioned medium of
PSCs and pre-stimulated PSCs also showed a slightly increased
expression of HMGA2 mRNA when compared to the control
spheroids (1.4-fold increase for PSC-conditioned medium and 1.6-
fold increase for conditioned medium from PDGF-BB pre-
stimulated PSCs; not significant) (Figure 5E).
We obtained similar data in a 3D spheroid co-culture model
allowing direct cell–cell contact between Panc-1 cells and PSCs.
The HMGA2 mRNA level was increased 1.7-fold in Panc-1 cells
grown in co-culture heterospheroids together with PSCs as
compared to Panc-1 control spheroids (Figure 5F).
Together these experiments demonstrate that fibroblasts can
support HMGA2 expression in a manner that is associated with
increased tumourigenic properties.
Table 1. Associations between HMGA2 expression and clinicopathological parameters
HMGA2 data 401a
Whole cohort (n¼401) PDAC (n¼251) AAC (n¼150)
HMGA2 expression Negative Positive P-value Negative Positive P-value Negative Positive P-value
n (%) 210 (52.4) 191 (47.6) 109 (43.4) 142 (56.6) 101 (67.3) 49 (32.7)
Age
p60 83 (20.7) 72 (17.9) 38 (15.1) 57 (22.7) 45 (30.0) 15 (10.0)
61–70 91 (22.7) 79 (19.7) 47 (18.7) 60 (23.9) 44 (29.3) 19 (12.7)
470 36 (9.0) 40 (10.0) 0.638 24 (9.6) 25 (10.0) 0.595 12 (8.0) 15 (10.0) o0.020*
Gender
Female 109 (27.2) 98 (24.4) 56 (22.3) 74 (29.5) 53 (35.3) 24 (16.0)
Male 101 (25.2) 93 (23.2) 0.921 53 (21.1) 68 (27.1) 1.000 48 (32.0) 25 (16.7) 0.730
Tumour localisation
Pancreas 109 (27.2) 142 (35.4)
Ampullary 101 (25.2) 49 (12.2) o0.001*
Treatment
No treatment 122 (30.4) 111 (27.7) 62 (24.7) 80 (31.9) 60 (40.0) 31 (20.7)
Gemcitabine 88 (21.9) 80 (20) 1.000 47 (18.7) 62 (24.7) 1.000 41 (27.3) 18 (12.0) 0.723
Stage group
Ia 15 (3.7) 10 (2.5) 9 (3.6) 9 (3.6) 6 (4.0) 1 (0.7)
Ib 33 (8.2) 12 (3) 10 (4.0) 6 (2.4) 23 (15.3) 6 (4.0)
IIa 52 (13) 50 (12.5) 28 (11.2) 36 (14.3) 24 (16.0) 14 (9.3)
IIb 97 (24.2) 110 (27.4) 59 (23.5) 90 (35.8) 38 (25.3) 20 (13.4)
III/IV 12 (3.0) 8 (2.0) 2 (0.8) 0 (0.0) 10 (6.7) 8 (5.3)
Missing 1 (0.25) 1 (0.25) o0.028* 1 (0.4) 1 (0.4) 0.260 0 (0.0) 0 (0.0) 0.367
Tumour differentiation
Well 85 (21.2) 35 (8.7) 49 (19.5) 24 (9.6) 36 (24.0) 11 (7.3)
Moderate 65 (16.2) 72 (18) 30 (11.9) 51 (20.3) 35 (23.3) 21 (14.0)
Poor/undifferentiated 54 (13.5) 80 (19.9) 24 (9.6) 63 (25.1) 30 (20.0) 17 (11.4)
Missing 6 (1.5) 4 (1.0) o0.001* 6 (2.4) 4 (1.6) o0.001* 0 (0.0) 0 (0.0) 0.286
Abbreviations: AAC¼ ampullary adenocarcinoma; PDAC¼pancreatic ductal adenocarcinoma. Associations were calculated, with Fisher’s Exact test, for the whole cohort and separately for the
two subsets of patients with PDAC or AAC. *Po0.05. aHMGA2 data available for 401 out of a total of 408 patients.
HMGA2 in PDAC and AAC BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.140 71
DISCUSSION
In the present study, we show by IHC analysis that HMGA2-
positivity is a strong prognostic factor for shorter overall survival
in PDAC and AAC (Tables 1 and 2). Notably, prognostic
association was also detected in multivariate analyses where
HMGA2 expression and tumour staging were the only significant
features (Table 1). Additional evidence for a role of HMGA2
expression as an independent marker of poor prognosis was
obtained by analyses of gene expression data from an
independent cohort of PDAC (Table 2). These findings,
including multivariable analyses and separate analyses of PDAC
and AAC, thus confirm and go well beyond findings of one
earlier study, which was limited to PDAC and included only
univariate survival analysis (Haselmann et al, 2014). Collectively
the findings suggest that HMGA2 IHC can identify patients with
a worse prognosis.
The long duration of sample collection, along with changes in
the clinical management of PDAC, make this tumour collection
unsuitable for analyses of possible relevance of HMGA2 as a
response-predictive marker. Such studies are warranted using other
tumour collections. Explorative analysis of the present collection
indicated that the survival association was equally strong in cases
that received or did not receive gemcitabine (Supplementary
Figure 1).
Among clinicopathological parameters a significant correlation
between HMGA2-positivity and lower tumour differentiation was
observed. However, within the clinical samples we did not find a
clear correlation between the HMGA2-protein and the expression
of EMT-specific miRNAs. Likewise, the HMGA2 gene expression
level showed no strong association with the expression of EMT
associated genes. HMGA2 could be detected in tumour cells
independent of their epithelial cell differentiation status, although
it appears enriched in tumour cells with low cytokeratin level
(Supplementary Figure 2B). Taken together, this data could suggest
that HMGA2 may be already induced at very early steps of tumour
dedifferentiation before the onset of EMT marker expression. Thus
far, it is unknown, when exactly HMGA2, normally expressed
during embryonic development, is re-induced during malignant
transformation. We and others (Abe et al, 2003; Piscuoglio et al,
2012), found HMGA2 to be absent in ductal epithelial cells of
normal pancreas tissue. Pancreatic ductal cells in patients with
chronic pancreatitis were also reported to be negative (Abe et al,
2003). Nevertheless, two studies observed an incipient positivity
for HMGA2 in non-neoplastic ductal cells from peritumoural
tissues of PDAC patients (Haselmann et al, 2014) as well as
within PanIN lesions (Piscuoglio et al, 2012). In the KPC
mouse model for PDAC, we detected weak Hmga2-positive cells
already within PanIN1 lesions (Figure 3). In contrast, we did not
detect any HMGA2-positive PanIN lesions within the human
samples.
Table 2. Multivariate analysis of overall survival
Total n (HMGA2 data) 408
a (401)
(n included in regression mode) Whole cohort (387) PDAC (240) AAC (147)
HR (95% CI)b P-value HR (95% CI)b P-value HR (95% CI)b P-value
Age
p60 1 1 1
61–70 1.26 (0.98 to 1.63) 1.29 (0.93 to 1.78) 1.15 (0.74 to 1.79)
470 1.66 (1.20 to 2.29) 0.008* 1.81 (1.21 to 2.70) o0.015* 1.30 (0.72 to 2.37) 0.661
Gender
Female 1 1 1
Male 0.98 (0.78 to 1.23) 0.868 0.91 (0.69 to 1.20) 0.509 1.09 (0.71 to 1.67) 0.694
Tumour localisation
Pancreas 1
Ampullary 0.70 (0.54 to 0.91) o0.009*
Treatment
No treatment 1 1 1
Gemcitabine 0.74 (0.57 to 0.96) o0.023* 0.83 (0.62 to 1.13) 0.240 0.52 (0.29 to 0.92) o0.025*
Stage groupc
Ia 1 1 1
Ib 1.32 (0.66 to 2.63) 0.91 (0.39 to 2.12) 4.04 (0.53 to 30.95)
IIa 2.27 (1.23 to 4.20) 1.69 (0.88 to 3.26) 6.78 (0.89 to 51.58)
IIb 3.54 (1.94 to 6.43) 2.64 (1.40 to 4.99) 10.44 (1.41 to 77.30)
III/IV 4.50 (2.07 to 10.22) o0.001* 4.21 (0.86 to 20.72) o0.001* 17.38 (2.19 to 138.21) o0.001*
Tumour differentiationd
Well 1 1 1
Moderate 1.08 (0.79 to 1.46) 1.24 (0.84 to 1.82) 0.96 (0.58 to 1.61)
Poor/undifferentiated 1.24 (0.93 to 1.66) 0.318 1.36 (0.95 to 1.95) 0.238 1.03 (0.60 to 1.77) 0.968
HMGA2e
Negative 1 1 1
Positive 1.93 (1.52 to 2.45) o0.001* 1.69 (1.26 to 2.26) o0.001* 2.55 (1.65 to 3.93) o0.001*
Abbreviations: AAC¼ ampullary adenocarcinoma; CI¼ confidence interval; HR¼ hazard ratio; PDAC¼pancreatic ductal adenocarcinoma. A Cox proportional hazard model was applied for the
whole cohort, as well as separately for the two subsets of patients with PDAC or AAC, including all variables were (n¼ 387 in whole cohort; n¼ 240 in PDAC; n¼ 147 in AAC). P-values are based
on Wald test. *Po0.05.
aFollow-up data missing for four patients (one in PDAC and three in AAC).
bHRs are estimated using proportional hazards regression with event defined as death.
cData missing for two patients.
dData missing for 10 patients.
eData missing for seven patients.
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Notably, the PanINs of the KPC model occurred predominantly
in context of extensive acinar-to-ductal metaplasia, which was not
a prominent feature in the human samples. These differences
suggest that although the KPC mouse is a good model of the
human disease, it also displays features not seen in human cases,
especially with regard to tumour initiation. Our findings suggest
that HMGA2 is differentially expressed in morphologically
divergent precursor lesions in mice and humans. Further studies
are therefore needed to determine at which stage(s) of human
tumour formation induction of HMGA2 is occurring.
Although several studies have described intrinsic signalling
pathways that regulate HMGA2 expression, there are only a few
studies that have investigated potential connections between the
tumour microenvironment and HMGA2-positivity. These studies
have focused on extracellular matrix components, including
collagen 1, rather than cell subsets of the tumour microenviron-
ment (Dangi-Garimella et al, 2011, 2013). Notably, in PDAC and
AAC the tumour stroma is a major part of the total tumour mass
(Lunardi et al, 2014a; Rucki and Zheng, 2014; Pan et al, 2015). Our
study provides experimental and correlative findings that link
PDGFRb-defined fibroblasts to HMGA2 status in malignant cells.
These correlative data, obtained both at case-level and through
double IHC analyses, strongly suggest that paracrine stroma-
epithelial signaling contributes to HMGA2 expression (Figure 4A
and B). These findings are in agreement with experimental and
translational studies which have emphasised the ability of cancer-
associated fibroblasts to control cancer cell stemness, EMT and
metastasis through paracrine signalling (Vermeulen et al, 2010;
Lonardo et al, 2011; Capparelli et al, 2012; Li et al, 2012; Malanchi
et al, 2011; Schulte et al, 2012). One very recent study nicely
demonstrated, that the specific heterotypic cell–cell interactions
between tumour cells carrying oncogenic KRASG12D and surround-
ing stroma cells are crucial to expand tumour cell signalling
beyond cell-autonomous signalling pathways in PDAC (Tape et al,
2016). Another group of tissue-based studies on different solid
tumours provided evidence for the existence of distinct fibroblast
subpopulations, marked, for example, by PDGFRb or increased
stromal expression of SNAIL, which correlate with the expression
of certain EMT markers in the adjacent tumour cells (Schulte et al,
2012; Galva´n et al, 2015; Senol et al, 2016). Importantly, a specific
link between CAFs, or any other stroma cell subtype, and cancer
cell expression of HMGA2 has not previously been demonstrated.
In earlier studies, the abundance of PDGFRb-defined stroma




Figure 3. Hmga2 expression during different stages of PDAC
development in the KPC mouse model. Representative
microphotographs of Hmga2 expression in the KPC mouse model of
pancreatic cancer. KPC PanIN-1 (upper left): minimal positivity of weak
intensity; KPC PanIN-1/2 (upper right): partial positive staining with
weak to moderate intensity mostly in PanIN-2; KPC PanIN-2 (middle
left): partial positive staining of weak to strong intensity; KPC PanIN-3
(middle right): diffuse positive staining of moderate to strong intensity;
KPC PDAC (lower left): heterogeneous positive staining, predominantly
in the poorer differentiated and sarcomatoid differentiated component;
KPC PDAC (lower right): heterogeneous positive staining,
































Figure 4. HMGA2-positive tumour cells are located in close proximity
to PDGFRb expressing cancer-associated fibroblasts. (A) Correlation
analysis of the abundance of PDGFRb-positive stroma cells and
HMGA2-positivity of tumour cells in patients with PDAC or AAC
(P-value based on Fisher’s Exact test). (B) Double IHC staining for
PDGFRb (blue) and HMGA2 (red) on samples selected to represent
human PDAC cases with low (upper picture) and high (lower picture)
HMGA2 expression. Scale bar, 100mm. **Po0.01.
HMGA2 in PDAC and AAC BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.140 73
and ovarian cancer (Paulsson et al, 2009; Ha¨gglo¨f et al, 2010;
Frings et al, 2013; Corvigno et al, 2016). Furthermore, experi-
mental therapy studies have shown anti-metastatic effects of
stroma-targeted therapies using PDGF inhibitors (Pietras et al,
2002, 2003a, b; Baranowska-Kortylewicz et al, 2005). Our
findings thus extend and support the few earlier clinical
correlative studies, in other tumour types, which have detected
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cancer cell expression of stem cell or EMT markers (Schulte et al,
2012).
Earlier studies have demonstrated that TGF-b as well as EGF
signalling can be inducers of HMGA2 (Thuault et al, 2006; Voon
et al, 2013) and we could confirm in our in vitro spheroid culture
system, that TGF-b treatment induces HMGA2 expression in
Panc-1 cells (Supplementary Figure 3B). Members of PDGF
ligands are unlikely to be part of the CAF-derived secretome that
induces HMGA2, since we found most PDAC cell lines as well as
tumour cells on tissue specimens to not express PDGFRs (data not
shown). Taken together, these findings motivate extended experi-
mental investigations on potential links between PDGFRb-defined
fibroblasts and TGF-b or EGF production. Especially the question
if stromal PDGFRb-signalling is actively involved or if the
PDGFRb is only a marker of a CAF-subpopulation that exhibits
a certain secretome inducing tumoral HMGA2 expression, needs
to be addressed.
Moreover, our data are also relevant in the context of recent
reports that discussed pro- as well as anti-tumoural effects of
fibroblasts in pancreatic cancer (Feig et al, 2013; O¨zdemir et al,
2014; Rhim et al, 2014). Collectively, these studies suggest that
multiple functionally distinct marker-defined fibroblasts exist in
pancreatic cancer. The findings of the present study strongly
support continued efforts to define novel fibroblast subsets for
further exploration of their regulation, function and clinical
associations.
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